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Association Between Blood Pressure Variability and Cerebral
Small-Vessel Disease: A Systematic Review and Meta-Analysis
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Background-—Research links blood pressure variability (BPV) with stroke; however, the association with cerebral small-vessel
disease (CSVD) remains unclear. As BPV and mean blood pressure are interrelated, it remains uncertain whether BPV adds
additional information to understanding cerebrovascular morphological characteristics.
Methods and Results-—A systematic review was performed from inception until March 3, 2019. Eligibility criteria included
population, adults without stroke (<4 weeks); exposure, BPV quantified by any metric over any duration; comparison, (1) low versus
high or mean BPV and (2) people with versus without CSVD; and outcomes, (1) CSVD as subcortical infarct, lacunae, white matter
hyperintensities, cerebral microbleeds, or enlarged perivascular spaces; and (2) standardized mean difference in BPV. A total of 27
articles were meta-analyzed, comprising 12 309 unique brain scans. A total of 31 odds ratios (ORs) were pooled, indicating that
higher systolic BPV was associated with higher odds for CSVD (OR, 1.27; 95% CI, 1.14–1.42; I2=85%) independent of mean systolic
pressure. Likewise, higher diastolic BPV was associated with higher odds for CSVD (OR, 1.30; 95% CI, 1.14–1.48; I2=53%)
independent of mean diastolic pressure. There was no evidence of a pairwise interaction between systolic/diastolic and BPV/mean
ORs (P=0.47), nor a difference between BPV versus mean pressure ORs (P=0.58). Fifty-four standardized mean differences were
pooled and provided similar results for pairwise interaction (P=0.38) and difference between standardized mean differences
(P=0.70).
Conclusions-—On the basis of the available studies, BPV was associated with CSVD independent of mean blood pressure.
However, more high-quality longitudinal data are required to elucidate whether BPV contributes unique variance to CSVD
morphological characteristics. ( J Am Heart Assoc. 2020;9:e013841. DOI: 10.1161/JAHA.119.013841.)
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E pidemiological studies show that cerebral small-vesseldisease (CSVD) subtypes are a common incidental
finding from brain imaging among older populations.1–6
Regularly identified CSVD subtypes include white matter
hyperintensities (WMHs), lacunae of presumed vascular
origin (LPVO), cerebral microbleeds (CMBs), and enlarged
perivascular spaces (EPVSs).7 The heightened risk for
stroke, dementia, depression, and mortality attributable to
CSVD8–10 underscores the importance of identifying mod-
ifiable vascular risk factors for the development and
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progression of CSVD to inform vascular risk management
among at-risk populations.11 Principle among vascular risk
factors for CSVD, and its clinical sequelae stroke and
dementia, is hypertension.12–14 Randomized controlled trials
(RCTs) and cohort studies provide mixed findings as to
whether elevated blood pressure (BP) and its management
with antihypertensive drugs mitigate CSVD risk and pro-
gression of CSVD.15–19 The inconsistency in findings raise
the possibility that factors beyond absolute BP level or
treat-to-target BP could be important for CSVD development
and progression.
A body of empirical work indicates that oscillation in BP
between consecutive measures holds additional prognostic
significance, alongside mean BP level, to predict subclinical
target organ damage, including in the brain.20,21 Once
considered background “noise” or measurement error,
intraindividual BP variation, known as BP variability (BPV),
holds prognostic value to predict incident and recurrent
stroke.22–24 Higher BPV has indirect effects on the brain,
including compromised cerebral autoregulation and tran-
sient hypoperfusion.25,26 Recent interest in BPV’s associa-
tion with brain morphological characteristics27,28 and
dementia,29,30 and debate surrounding the clinical relevance
of BPV to stroke31,32 and how to define and analyze
BPV,33,34 underscores the topical nature of BPV to brain
health.
Previous meta-analyses on BPV reported associations with
acute stroke and transient ischemic attack (TIA),24,35 head-
ache,36 atrial fibrillation,37 left ventricular mass index,38
mortality,39 cardiovascular outcomes,40 and multiple end
points, including, stroke, mortality, and cardiovascular
outcomes.41 Other systematic reviews and guidelines have
focused on the statistical methods and technical aspects of
quantifying BPV.34,42,43 This systematic review adds to
previous reviews by quantifying the association between
BPV with CSVD using meta-analytic techniques. The objective
of this review is to quantify the association between
intraindividual BPV and CSVD in populations without recent
stroke (subacute <4 weeks). A second objective is to
compare the magnitude of association between BPV and




This review conforms to the guidelines outlined in the
Preferred Reporting Items for Systematic Reviews and Meta-
Analyses statement (Table S1).44 A protocol was registered on
PROSPERO (International Prospective Register of Systematic
Reviews) (CRD42017081974). A systematic search of the
MEDLINE, EMBASE, and SCOPUS electronic databases was
performed from database inception without language restric-
tions; the last search was performed on March 3, 2019
(search string Table S2). Studies from database inception
were eligible, as we had no a priori justification to limit studies
to a certain era. The authors declare that all supporting data




The population of interest included participants aged
≥18 years who had BP quantified using a standardized
measure, in which intraindividual BPV (systolic, diastolic, or
both) was calculated and participants underwent brain
imaging to determine CSVD (defined further below) by
computed tomography (CT) or magnetic resonance imaging
(MRI). Quantification of mean BP within samples, although
desirable for our comparative analysis, was not a prespec-
ified inclusion criterion, nor was the reporting of hyperten-
sion or systolic/diastolic load. Likewise, the use of BPV
metrics accounting for interdependence with mean BP was
not a prespecified inclusion criterion (eg, variance indepen-
dent of the mean). Studies including people with a past
stroke or TIA were eligible if: (1) the measurement of BPV
and CSVD was not in the subacute stage (ie, <4 weeks)
after a cerebral event requiring hospitalization and (2) the
point prevalence of previous stroke or TIA did not exceed
50% of the sample. The rationale was that impaired BP
Clinical Perspective
What Is New?
• Blood pressure (BP) variability was associated with cerebral
small-vessel disease independent of mean BP in a pooled
meta-analysis of 27 articles and 12 309 unique brain scans.
• There was no evidence of a pairwise interaction between
systolic/diastolic and BP variability/mean BP effect sizes.
• The strength of evidence was rated as low for all primary
outcomes.
What Are the Clinical Implications?
• The association between BP variability with cerebral small-
vessel disease, independent of mean BP, may have impli-
cations for the monitoring of BP and selection of antihy-
pertensive drugs that minimize BP variability in people with
cerebral small-vessel disease.
• The strength of evidence was too low to make definitive
clinical recommendations.
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regulation in the acute and subacute stage would likely be a
consequence of stroke45 and that the association between
BPV with stroke outcomes has already been extensively
quantified by meta-analysis.23,24
Comparator/control
A bidirectional association was considered between BPV and
CSVD. The analyses used comparator groups consisting of
people with low BPV versus high BPV for outcome 1 and
people without CSVD or with low severity of CSVD for the
comparison of BPV means in outcome 2.
Outcomes
1. The association between BPV in any metric (independent
variable) with the presence of CSVD determined by brain
imaging with CT or MRI (dependent variable). CSVD subtypes
were considered in the following categories:
Recent small subcortical infarct: ≤20 mm in the territory of
one perforating arteriole.
LPVO: 3- to 15-mm round or ovoid, subcortical, fluid-filled
cavity (similar signal as cerebrospinal fluid), consistent
with a previous acute small deep brain infarct or hemor-
rhage in the territory of one perforating arteriole with
hyperintense rim.7
Cerebral white matter changes or hyperintensity: hyperin-
tense on T2-weighted sequences, isointense or hypoin-
tense on T1-weighted sequences,7 or hypodense on CT,46
determined by either visual grading with a recognized scale
(eg, Fazekas, Scheltens, or Rezek)46,47 or volumetry (fully
or semiautomated).
CMBs: small hypointense lesions (round or ovoid blooming;
≤10 mm) that are visible on paramagnetic-sensitive MR
sequences, such as T2*-weighted gradient-recalled echo or
susceptibility-weighted sequences.7
EPVSs: also known as Virchow-Robin spaces, a fluid-filled
space ≤2 mm that follows the typical course of a vessel as
it goes through gray or white matter, with similar signal
intensity to cerebrospinal fluid.7
2. Mean difference in BPV (dependent variable) between people
with and without CSVD (independent variable). Mean differences
were extracted by either the presence or the absence of CSVD or
severity (eg, on Fazekas scale). All BPV metrics derived from
ambulatory BP monitoring (ABPM), home BP monitoring, or visit-
to-visit assessments were eligible on the basis of Rothwell’s
definition of intraindividual BPV,22 including but not limited to SD,
average real variability, and coefficient of variation.34
Study design
Quantitative studies of any design were eligible, including
case-control, cohort, database registry, or RCT. No restriction
was placed on sample size.
Exclusion Criteria
Studies were excluded if the study was performed on animal
subjects; BPV was quantified during the acute or subacute
stage (ie, <4 weeks) of stroke or TIA; BPV was reported in the
context of BP instability, stress reactivity, or postural change,
such as experimental designs with a stress challenge,
orthostatic change, or head-up tilt-table testing; the cohort
was designed to test the prognosis of coronary revascular-
ization or renal denervation, or the cohort was designed to
assess dementia, Parkinson disease, leukodystrophy, or other
degenerative neurological disorder prognosis; the report
described a case study; effect size data could not be
extracted, calculated, or provided by the study authors; or
the study reported only brain atrophy or brain volume.
Inconsistencies in brain imaging terminology are well docu-
mented.7,48 To optimally harmonize end points, cerebral
infarctions >20 mm diameter were excluded from analyses
irrespective of terminology (eg, lacunar infarction and lacunar
stroke syndrome).
Literature Screening
Three reviewers (P.J.T., K.G., and M.O.) independently
screened titles and abstracts of all the retrieved bibliograph-
ical records for eligibility using a data abstraction protocol.49
A hand search was performed of the articles selected for full-
text review and of narrative reviews,50–53 supplementing the
electronic search. In the case of title/abstract review
disagreements, the study was subjected to full-text review.
After determination of the study eligibility, data extraction was
undertaken independently by 3 reviewers (P.D.P., K.G., and
E.J.L.L.) and verified by a fourth reviewer (P.J.T.) to reduce
reviewer errors, reduce bias, and achieve consensus. The data
extracted pertained to study identification (first author, year of
publication, country where recruitment took place, and name
of study or trial), study design characteristics (sample size and
study design) of the population under study (age, sex, use of
antihypertensive medication, and prevalence of stroke), BP
and BPV exposure (type of measure, BPV metrics, duration of
BP measures, and observation period), CSVD adjudication
(subtypes and definition and imaging methods), effect size
(most adjusted effect size or raw numbers) adjustment for
covariates (list of variables), and funding (grant numbers or
acknowledgement).
A request for additional published, unpublished, and in
progress articles was sent through the Variability in Blood
Pressure and Brain Health consortium (members listed in
acknowledgements).54 The principal investigators of eligible
studies were contacted to clarify published and unpublished
data and duplicate articles. Study authors were contacted via
e-mail to request the unreported data. If the initial e-mail was
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not replied to within 2 weeks, a second e-mail was subse-
quently sent. Confirmation of ineligible data was provided by 1
author,55 eligibility was confirmed for 2 studies,56,57 and
additional unpublished data were provided by 2 studies.58,59
Risk of Bias
The RTI item bank was used to identify methodological bias
for primary outcomes 1 and 2 for all studies.60 Risk of bias
assessment was undertaken by 2 reviewers (E.J.L.L. and P.J.T.)
with consensus achieved after discussion. Adjudication of the
strength of evidence for the primary CSVD outcome and
between-group differences was made according to the
Grading of Recommendations Assessment, Development
and Evaluation (GRADE) criteria with GRADE Profiler 3.6.1.61
CSVD Grouping and Outcome Adjudication
1. Primary outcome odds for CSVD attributable to BPV: If BPV’s
association with CSVD was reported for >1 CSVD subtype, we
prioritized the analysis with the largest number of CSVD end
points, handling CSVD subtypes in stratified analyses. If
models were adjusted, we extracted data from the most
adjusted model. In instances where different levels of
adjustment were made for mean and BPV data, we prioritized
data from the same model to ensure equivalence in covariate
adjustment. When >1 BPV metric was reported for CSVD
subtypes, we prioritized the most adjusted model and models
with the largest number of participants. If multiple metrics
were available after applying this hierarchy, we extracted both
outcomes and reported in sensitivity analyses.
2. Difference between groups in CSVD: If BPV meanSD
was reported in different CSVD pathological conditions or
severities, the subgroup with the highest N was used,
prioritizing statistical power over severity,62 ensuring one
effect size was analyzed per study rather than collapsing
CSVD groups.63 For the mean difference between CSVD
groups, we prioritized the most common method of BPV in
primary analyses (SD method) and reported other metrics in
sensitivity analyses.
1 and 2. BPV data were extracted and prioritized in order,
as follows: 24-hour ABPM, awake ABPM measures (versus
sleep), office/clinic/casual (commonly referred to as visit to
visit), and home BP monitoring.
Mean BP
Mean BP data were extracted for eligible studies. Odds ratios
(ORs) and risk ratios for CSVD were standardized to 10/5–
mm Hg increase, multiplying the log of the summary statistic
by 10/5, depending on whether systolic BP or diastolic BP
was being modeled. It was not possible to standardize the OR
effect sizes per SD increase because of inconsistent reporting
in the original studies. Between CSVD group differences in BP
were modeled with standardized mean differences (SMDs);
thus, no standardization was necessary.
Statistical Analysis
Primary outcome 1 was analyzed in R, version 3.5.2, using
the metafor package. A multilevel meta-analysis was per-
formed.64 A key advantage of a multilevel meta-analysis,
compared with a traditional meta-analysis, is that a single
study contributes multiple effect sizes (eg, systolic BP,
systolic BPV, diastolic BP, and diastolic BPV). Moreover, a
multilevel meta-analysis accounts for the dependence in
effect sizes within a study (ie, between BPV and mean BP,
from which BPV is often calculated; and dependence of
systolic and diastolic BP). A mixed effects model, with a
random intercept per study, tested fixed effect moderators
for BP type (diastolic versus systolic) and measure (mean
versus variability) and their pairwise interaction. The hetero-
geneous CSVD subtypes were pooled together in the first
instance as each is presumed to have a predominant
ischemic origin7 and CSVD is considered a whole-brain
disease.48 Likewise, ABPM, home, and visit-to-visit variability
data were pooled together, consistent with a previous
review,41 as short- and longer-term BPVs are correlated65
and share some postulated mechanisms, such as arterial
reflex and compliance, and dosing/titration of antihyperten-
sive drugs.21 Original data pertaining to the likelihood of
CSVD were reported as OR and risk ratio with 95% CIs. The
estimates were pooled together in a meta-analysis because
they are presumed to measure the same underlying effect,66
and consensus exists that these are approximately equiva-
lent for effect sizes <2.5 and follow-up <20 years.67 Primary
outcome 1 was analyzed stratified by CSVD subtype, BPV
metric, day versus night ABPM measures, oscillometric
versus auscultatory method of BP measurement, ABPM
versus home or visit-to-visit BPV, visit-to-visit interval <6 and
>6 months, use of MRI versus CT with or without MRI, and
Asian versus non-Asian populations in ancillary analyses with
RevMan, version 5.3.68 The latter stratification is because of
the purported higher morning surge component of BPV
among Asian populations.69
The association between BPV and WMHs was modeled
with RevMan, version 5.3,68 for d family effect sizes and
Comprehensive Meta-Analysis software70 for r family effect
sizes. To demonstrate the association between BPV and the
CSVD subtype of WMH, the study effect sizes was reported as
r (continuous outcome but no grouping by BPV) or d family
(continuous or dichotomized, with grouping by BPV). Because
no BPV subgroups were reported in the r family studies, the
effect sizes were ineligible for combined pooling and were,
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thus, pooled separately. The r family effect sizes were pooled
with Comprehensive Meta-Analysis (CMA) software, which
converts r values to Fisher Z distribution. In the studies where
standardized b values were reported,28,63,71,72 these values
were converted to r using the formula outlined by Peterson
and Brown73: r=0.98b+0.05k, where k is an indicator variable
that equals 1 when b is nonnegative and 0 when b is negative.
The formula applies to b values between 0.50 and 0.50.
The SMD in BPV between people with and without CSVD
was pooled in R, version 3.5.2, using the metafor package,
testing mixed effects models with a random intercept per
study and fixed effect moderators for BP type (diastolic
versus systolic) and measure (mean versus variability) and
their pairwise interaction. The effect sizes (Hedges g) were
interpreted according to Cohen’s74 criteria: 0.2 represents a
small effect; 0.5, a moderate effect; and 0.8, a large effect.
In studies that reported BPV mean and no SD or SE (eg,
interquartile range), we calculated the t-statistic using the P
value with RevMan and then calculated the SMD using the
methods outlined by Hedges and Olkin.75 SMD analyses
were stratified by BPV metric, day versus night ABPM
measures, oscillometric versus auscultatory method of BP
measurement, ABPM versus home or visit-to-visit BPV, visit-
to-visit interval <6 and >6 months, use of MRI versus CT,
and Asian versus non-Asian populations in ancillary analyses
using RevMan.
Random effects models (inverse-variance method) were
used regardless of statistical heterogeneity under the
assumption of high sampling variability between studies,
different BPV metrics, and CSVD outcomes.34 Statistical
heterogeneity was evaluated with the I2 statistic: I2=0%–60%
(not important to moderate), and I2 >60% (substantial
statistical heterogeneity).76 Methodological heterogeneity
was explored with meta-regression in relation to the primary
outcomes, examining mean or median age, proportion of
women, antihypertensive treatment or hypertension, preva-
lence of previous stroke or TIA, body mass index (kg/m2), and
tesla size of MRI (coded 0 for CT). It was not possible to
perform a meta-regression with BP dipping because of
inconsistent reporting within studies. The presence of publi-
cation bias was evaluated with the test of Egger et al,77 the
test of Begg and Mazumdar,78 and Duval and Tweedie’s trim-
and-fill funnel plot.79
Results
Study Selection and Characteristics
The search yielded 8304 citations, from which 51 were
reviewed in detail and 27 articles were retained (Table S3 and
Figure S1). One study was close to meeting the inclusion
threshold80; however, in this study, BPVwas reported in relation
to white matter integrity and brain health, quantified with
fractional anisotropy. The 27 included articles reported on 26
unique samples, comprising a pooled sample of 12 309 unique
brain scans, amean sample size of 473 participants per study, a
mean age of 73.05.2 years, 48.817.6% women, a mean
55.827.1% with hypertension or using antihypertensive
treatment, a 5.1% stroke prevalence at baseline, and a mean
body mass index of 26.21.9 kg/m2 (study characteristics in
Tables S4 and S5). The included studies originated primarily
from Asia (10 studies), Europe (9 studies), and North America (7
studies), with 1 of these recruiting Americans with Japanese
ancestry.81 Studies were mostly cohort designs (13 studies),
cross-sectional (6 studies), or case-control (5 studies). One
sample was reported as both cross-sectional and cohort, and 1
study was RCT design. Most studies used MRI, 3 studies used
CT, and only 1 study used MRI and CT. In 1 study, the imaging
protocol was unclear. The studies using CT only reported data
for analysis of primary outcome 2, SMDs in BPV. Most studies
quantified WMH (n=20) or LPVO (n=7), with 6 studies including
multiple CSVD outcomes, and few studies quantified CMBs or
EPVSs (Table S6).
Assessment of Risk of Bias
The adjudication of risk of bias and precision is provided in
Table S7. In 10 studies, inclusion criteria were insufficiently
described. Seven studies were deemed underpowered to
detect an effect size for the primary outcomes. Most studies
(n=21) reported blinded outcome adjudication. Generally, BP
was assessed with reliable methods, such as ABPM or clinic
visit to visit with standardized protocols; 3 studies were rated
as low for description of exposure.
Primary Outcome 1: Association Between BPV
and CSVD
Systolic and diastolic BPV and risk for CSVD
A total of 31 estimated ORs were reported: 13 for systolic
BPV, 9 for mean systolic BP, 6 for diastolic BPV, and 3 for
diastolic BP. Higher systolic BPV was associated with higher
odds for CSVD (OR, 1.27; 95% CI, 1.14–1.42; I2=85%),
independent of mean systolic BP per 10–mm Hg increase
(OR, 1.17; 95% CI, 1. 09–1.25; I2=52%) (Figure 1). Likewise,
higher diastolic BPV was significantly associated with higher
odds for CSVD (OR, 1.30; 95% CI, 1.14–1.48; I2=53%),
independent of mean diastolic BP per 5–mm Hg increase (OR,
1.14; 95% CI, 1.10–1.19; I2=0%). There was no evidence of a
pairwise interaction between BP type (diastolic versus
systolic) and measure (mean versus variability; P=0.47;
Akaike information criterion=1.5), nor was there evidence
of a difference between measures (mean versus variability;
P=0.58; Akaike information criterion=6.6).
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Figure 1. Forest plot showing the association between blood pressure variability (BPV) and mean blood pressure (BP) with odds for cerebral
small-vessel disease (CSVD). Data are presented numerically (log odds ratio [OR] and SE) and graphically (forest plot), showing the CSVD risk in
each of the included studies and the pooled effect size, stratified by systolic BPV and mean systolic BP per 10–mm Hg increase and diastolic
BPV and mean diastolic BP per 5–mm Hg increase. Effect sizes are presented graphically (OR and 95% CI), and those to the right of the vertical
line (OR=1) indicate higher odds for CSVD. Data were pooled together using the inverse variance method with random effects. IV indicates
inverse variance.
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Primary Outcome 2: Between CSVD Group
Comparison on Mean BPV
Systolic and diastolic BPV and mean BPV
Fifty-four SMDs were reported between individuals with and
without CSVD: 15 for systolic BPV, 13 for mean systolic BP,
14 for diastolic BPV, and 12 for diastolic mean BP. Systolic
BPV was significantly higher in CSVD populations compared
with their non-CSVD counterparts (g=0.21; 95% CI, 0.13–
0.28; I2=28%), as was mean systolic BP (g=0.28; 95% CI,
0.18–0.38; I2=44%); however, the effect sizes were small
(Figure 2). Likewise, diastolic BPV was higher in people with
CSVD compared with their non-CSVD counterparts (g=0.13;
95% CI, 0.08–0.19; I2=0%), as was mean diastolic BP (g=0.12;
95% CI, 0.00 to 0.24; I2=66%), although effect sizes were
small. There was no evidence of a pairwise interaction
between BP type (diastolic versus systolic) and measure
(mean versus variability; P=0.38; Akaike information crite-
rion=13.4), nor was there evidence of a difference between
measures (mean versus variability; P=0.70; Akaike informa-
tion criterion=18.4).
Meta-Regression
The meta-regression results on the primary outcomes are
presented in Table S8. Odds for CSVD attributable to systolic
BPV were associated with increased age, nonuse of antihy-
pertensives or hypertension, stroke prevalence, body mass
index, and increased tesla of MRI. Odds for CSVD attributable
to diastolic BPV were associated with younger age and stroke
prevalence. Difference between people with and without
CSVD in systolic BPV was associated with younger age,
whereas difference between CSVD groups in diastolic BPV
was associated with female sex; the effect for MRI tesla was
marginal (P=0.061).
Publication Bias and GRADE Rating of Primary
Outcomes
Evidence of publication bias was suspected for odds of CSVD
attributable to systolic and diastolic BPV, evidenced by the
test of Egger et al77 and the funnel plot trim-and-fill method,
although only 6 diastolic BPV studies were retrieved by our
systematic review (Table S9 and Figures S2 through S5).
GRADE rating of the quality of evidence was low for all
outcomes across systolic and diastolic BPV metrics
(Table S10).
Ancillary Analyses
The ancillary analyses stratified by CSVD subtype are
presented online (Tables S11 and S12). Ancillary analyses
by BPV metric, day versus night ABPM measures, ABPM
versus home or visit-to-visit BPV, visit-to-visit interval <6 and
>6 months, use of MRI versus CT with or without MRI, and
Asian versus non-Asian populations are reported in
Tables 182–90 and 2.91–98 The ancillary analyses supported
an association between systolic BPV with total and periven-
tricular WMH, but not other subtypes. The association
between systolic and diastolic BPV in primary outcomes 1
and 2 was generally replicated and consistent when stratified
by different methodological factors. Specifically, primary
outcome 1 demonstrated comparable magnitude of ORs
when stratified by day versus night and 24-hour ABPM versus
home BP monitoring and visit-to-visit BPV. There was,
however, evidence of heterogeneity between Asian and non-
Asian systolic BPV effect sizes for primary outcome 1.
Likewise, for primary outcome 2, comparable magnitude of
SMDs was evident when analyses were stratified by day
versus night and 24-hour ABPM versus home BP monitoring
and visit-to-visit BPV, as well as Asian versus non-Asian
populations.
Discussion
This systematic review and meta-analysis indicated a higher
odds for CSVD attributable to systolic BPV, independent of
mean BP. Published data were significant but sparse for
diastolic BPV and CSVD risk. When SMDs in BPV were
compared between people with and without CSVD, higher
systolic and diastolic BPV means were evident in CSVD
populations, independent of mean BP. There was no evidence
of a pairwise interaction between BP type (diastolic versus
systolic) and measure (mean versus variability), nor was there
evidence of a difference between measures (mean versus
variability) for primary outcomes 1 and 2. Collectively, these
findings suggest that BPV is associated with CSVD, indepen-
dent of mean BP, in the retained articles. The findings were
derived from mainly cross-sectional articles, with moderate to
high heterogeneity and suspicion of publications bias; there-
fore, the GRADE rating of evidence was low for all primary
outcomes.
The association between BPV with CSVD reported herein
sits alongside previous BPV systematic reviews relating to
neurological outcomes, including acute stroke or TIA24 and
headache.36 Rothwell and colleagues23 demonstrated the
predictive utility of BPV in relation to incident and recurrent
strokes by investigating ratio of variances and variance
independent of the mean among antihypertensive drug versus
placebo RCTs. By contrast, our review included only included
1 RCT, which might explain why the use of antihypertensive
drug or hypertension prevalence at baseline was largely
unrelated to CSVD effect sizes in the meta-regression.
Differential effects of antihypertensive drug classes on BPV
DOI: 10.1161/JAHA.119.013841 Journal of the American Heart Association 7
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Figure 2. Forest plot showing the standardized mean difference (SMD) between cerebral small-vessel
disease (CSVD) groups on blood pressure variability (BPV) and mean blood pressure (BP). Data are presented
numerically (SMD as Hedges g and SE) and graphically (forest plot), showing the between CSVD group
difference in each of the included studies and the pooled effect size, stratified by systolic BPV andmean systolic
BP and diastolic BPV and mean diastolic BP. Effect sizes are presented graphically (Hedges g and 95% CI), and
those to the right of the vertical line (SMD=0) indicate higher systolic BPV or BP in populations with CSVD. Data
were pooled together using the inverse variance method with random effects. IV indicates inverse variance.
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Table 1. Ancillary Analysis Results for Odds of CSVD, Stratified by BPV Metric, BP Measurement, and CSVD Assessment
BP Measure Type of BPV Metric No. of StudiesReferences OR 95% CI I2
Systolic SD 627,57,83,88–90 1.28* 1.19–1.39* 0
Weighted SD 289,90 1.75* 1.38–2.22* 0
Coefficient of variation 627,58,86,88–90 1.36* 1.12–1.67* 88
Variance independent
of the mean
188 1.23 1.05–1.44 
Successive variation 188 1.00 0.91–1.10 
Average real variability 282,89 1.18 * 1.03–1.35* 2
Variance in residuals 281,84 1.36 0.66–2.79 71
Oscillometric 1027,57,58,82,83,85–87,89,90 1.29* 1.13–1.48* 88
Auscultatory 381,84,88 1.18 0.95–1.46 62
Day† 427,82,83,90 1.25* 1.08–1.46* 72
Night† 427,82,83,90 1.19* 1.05–1.34* 63
24-h ABPM 727,57,82,83,86,89,90 1.26* 1.09–1.47* 82
HBPM and visit to visit 658,81,84,85,87,88 1.27* 1.11–1.45* 70
Visit-to-visit BP interval <6 mo 287,88 1.24* 1.06–1.44* 0
Visit-to-visit BP interval >6 mo 358,81,84 1.21 0.96–1.51 71
MRI only 1327,57,58,81–90 1.27* 1.14–1.42* 85
CT with or without MRI    
Primarily Asian 727,57,62,81,88–90 1.42* 1.27–1.58* 36
Non-Asian 658,82,84,86,87,97 1.13 * 1.02–1.26* 73
Diastolic SD 288,89 1.24* 1.03–1.50* 0
Weighted SD 189 1.97 1.06–3.66 
Coefficient of variation 427,58,88,89 1.33* 1.10–1.60* 63
Variance independent
of the mean
188 1.20 0.98–1.47 
Successive variation 188 1.08 0.95–1.23 
Average real variability 189 1.56 0.89–2.73
Variance in residuals    
Day† 227,90 1.46* 1.23–1.74* 0
Night† 227,90 1.27* 1.11–1.47* 23
Oscillometric 427,58,87,89 1.56* 1.19–2.04* 56
Auscultatory 284,88 1.15 1.05–1.27 0
24-h ABPM 227,89 1.86 * 1.36–2.55* 0
HBPM and visit to visit 458,84,87,88 1.22* 1.14–1.31* 13
Visit-to-visit BP interval <6 mo 287,88 1.35 0.95–1.92 48
Visit-to-visit BP interval >6 mo 258,84 1.19* 1.09–1.29* 15
MRI only 627,58,84,87–89 1.30* 1.14–1.48* 53
CT with or without MRI    
Primarily Asian 327,88,89 1.53 * 1.08–2.16* 63
Non-Asian 358,84,87 1.21* 1.08–1.37* 42
ABPM indicates ambulatory BP monitoring; BP, blood pressure; BPV, BP variability; CSVD, cerebral small-vessel disease; CT, computed tomography; HBPM, home BP monitoring; MRI,
magnetic resonance imaging; OR, odds ratio.
*Significant values (when ≥2 studies).
†Any metric of BPV recorded from ABPM and subdivided by day and night measures.
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Table 2. Ancillary Analysis Results for SMDs in BPV, Stratified by BPV Metric, BP Measurement, and CSVD Assessment
BP Measure Type of BPV Metric No. of StudiesReferences Hedges g 95% CI I2
Systolic SD 1227,56,57,72,82,88–91,93–95 0.17* 0.09 to 0.26* 9
Weighted SD 457,82,89,90 0.17* 0.09 to 0.26* 0
Coefficient of variation 927,58,82,88–90,94–96 0.21* 0.12 to 0.30* 14
Variance independent
of the mean
188 0.13 0.17 to 0.43 
Successive variation 188 0.15 0.15 to 0.45 
Average real variability 282,89 0.35* 0.18 to 0.53* 0
Variance in residuals    
Day† 627,57,82,90,91,94 0.13* 0.03 to 0.23* 17
Night† 627,57,82,90,91,94 0.21* 0.08 to 0.35* 35
Oscillometric 1327,56–58,72,82,89–95 0.22* 0.14 to 0.30* 34
Auscultatory 288,96 0.09 0.14 to 0.32 0
24-h ABPM 1227,56,57,72,82,90–95 0.22* 0.12 to 0.31* 38
HBPM and visit to visit 358,88,96 0.21* 0.11 to 0.31* 0
Visit-to-visit BP interval <6 mo 188 0.16 0.14 to 0.47 
Visit-to-visit BP interval >6 mo 258,96 0.18 0.02 to 0.39 38
MRI only 1127,56–58,72,82,88–92 0.21* 0.13 to 0.29* 27
CT with or without MRI 493–96 0.21 0.12 to 0.53 48
Primarily Asian 827,57,88–90,95,96,98 0.20* 0.11 to 0.29* 16
Non-Asian 756,58,72,82,91,93,94 0.21* 0.06 to 0.36 * 46
Diastolic SD 1127,56,57,72,82,88–91,93,94 0.07* 0.00 to 0.14* 0
Weighted SD 357,89,90 0.14 0.03 to 0.31 42
Coefficient of variation 827,58,82,88–90,94,96 0.20* 0.13 to 0.28* 0
Variance independent
of the mean
188 0.21 0.09 to 0.51 
Successive variation 188 0.29 0.01 to 0.59 
Average real variability 282,89 0.19* 0.01 to 0.36* 0
Variance in residuals    
Day† 627,57,82,90,91,94 0.06 0.02 to 0.14 0
Night† 627,57,82,90,91,94 0.09* 0.01 to 0.18* 0
Oscillometric 1227,56–58,72,82,89–94 0.14* 0.08 to 0.20* 0
Auscultatory 288,96 0.08 0.20 to 0.36 30
24-h ABPM 1127,56,57,72,82,89–94 0.10 * 0.03 to 0.16* 0
HBPM and visit to visit 358,88,96 0.19 * 0.02 to 0.35* 34
Visit-to-visit BP interval <6 mo 188 0.21 0.09 to 0.51 
Visit-to-visit BP interval >6 mo 258,96 0.13 0.18 to 0.45 67
MRI only 1127,56–58,72,82,88–92 0.14* 0.08 to 0.20* 1
CT with or without MRI 393,94,96 0.01 0.24 to 0.21 0
Primarily Asian 727,57,88–90,96,98 0.10* 0.02 to 0.17* 0
Non-Asian 756,58,72,82,91,93,94 0.20* 0.10 to 0.29* 0
ABPM indicates ambulatory BP monitoring; BP, blood pressure; BPV, BP variability; CSVD, cerebral small-vessel disease; CT, computed tomography; HBPM, home BP monitoring; MRI,
magnetic resonance imaging; SMD, standardized mean difference.
*Significant values (when ≥2 studies).
†Any metric of BPV recorded from ABPM and subdivided by day and night measures.
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over the short- and long-term are documented, implicating
calcium channel blockade and thiazide diuretics in optimal
BPV control,24,99 which might modulate the effects of BPV on
CSVD.
In this review and previous systematic reviews,24,36–41 the
effect sizes for BPV were pooled together concurrently with
mean BP effect sizes. However, our meta-analysis used
multilevel modeling to account for within-study dependence
between mean and BPV, as well as systolic and diastolic
effect sizes.64 There was generally no evidence for an
interaction or heterogeneity between BPV and mean BP
pooled effect sizes herein, suggesting that each is associated
with CSVD and offers unique variance, and potentially that the
magnitude of association with CSVD is comparable between
mean and BPV effect sizes. One exception to this finding from
ancillary analyses was that mean systolic BP but not systolic
BPV increased risk for incident CSVD. Our pooled analyses
are, however, limited by only modeling mean BP in the studies
investigating BPV. It is likely that including all CSVD studies
reporting mean BP, but not necessarily BPV, would quantify
heterogeneity between effect sizes more robustly. This could
be important given that mean and other indexes of BP (eg,
pulse pressure, mean arterial pressure, and morning surge)
are associated with CSVD.98,100
There were sparse published data for CSVD subtypes apart
from WMH. WMH data were inconsistently reported and thus
pooled separately for r and d family effect sizes. When total as
well as deep and periventricular WMH volumes were pooled,
the significant association with total WMH was largely
attributable to periventricular and not deep WMH volumes.
This finding contrasts to the conclusion by Kim and
colleagues101 that irregular periventricular WMHs are uniquely
associated with chronic hemodynamic insufficiency or hypop-
erfusion caused by carotid atherosclerosis, whereas deep
WMHs are more causatively related to hypertension and
CSVD. Further investigation of BPV and regional WMH
volumes could be an important avenue of future work, given
that periventricular WMH burden is particularly implicated in
cognitive decline in processing speed and executive function
domains.102,103 Recent studies indicate that BPV is associ-
ated with dementia and cognitive decline,29,30,104–106 raising
the possibility that BPV’s impact on brain health might be
through periventricular white matter pathways susceptible to
chronic hemodynamic insufficiency or hypoperfusion.101 As
most published BPV data pooled herein relate to WMH, it is
important to explore other pathways that lead to the
development or progression of CSVD subtypes, such as
LPVO,57,58,86,87 CMBs,87 and EPVSs.27
A lack of consensus on BPV methods contributes to
substantial heterogeneity between studies with 36 different
variability metrics (class, type, and timing) identified in a
systematic review of ABPM studies by Taylor and
colleagues.34 Moreover, there is no consensus on the optimal
metrics to study BPV independent of mean BP and the
number of measurements required to quantify visit-to-visit
BPV for risk stratification.99 Because of this uncertainty in
BPV measurement, we pooled different BPV metrics sepa-
rately in ancillary analyses and found generally consistent
results for the most common metrics (SD, coefficient of
variation, and average real variability) for primary outcomes 1
and 2. Most studies reported either ABPM or visit-to-visit
variability. The magnitude of association between systolic BPV
and CSVD was comparable in studies adopting ABPM versus
home or visit-to-visit variability for both primary outcomes.
This finding suggests that both short- and long-term systolic
BPVs are related to CSVD or that they share similar
mechanisms insofar as the relationship with CSVD is
concerned. Although the mechanisms underlying BPV are
poorly understood, short- and longer-term BPVs are hypoth-
esized to both reflect arterial reflex and compliance and
dosing/titration of antihypertensive medications.21 Previously
meta-analytic findings indicate that long-term BPV is associ-
ated with cardiovascular outcomes and mortality, although
ABPM evidence was sparse.41 Further direct comparisons of
ABPM and long-term BPV in CSVD are important given that
casual cuff BPV measures are less predictive of stroke than
those obtained from ABPM107 and the mechanisms remain
uncertain.21
This review found mixed evidence for discrete differences
in BPV between Asian and non-Asian populations. The risk for
CSVD attributable to systolic BPV was higher among Asian
populations; however, there were no observed differences in
SMDs of either systolic or diastolic BPV. Kario and Wang69
posited that Asian populations exhibit higher morning surge in
BP, a pressor component of BPV. The observed higher odds
for CSVD in Asian populations was unlikely caused by method
given that a comparable number of studies used 24-hour
ABPM in the primarily Asian and non-Asian studies (4 versus
3). Potentially, the data derived from new investigations in
Asian subpopulations could identify the extent to which BPV
and its pressor components differ among people with and
without CSVD.108,109
The strengths of this study include the large pooled
sample, meta-regression, and ancillary analyses by CSVD
subtypes, BPV metric, and BP measurement intervals. Several
limitations temper the results of this review, including
suspicion of publication bias. The included studies were
predominantly case-control or cohort studies and thereby are
prone to inherent biases, such as selection bias, attrition, and
unmeasured confounding. Examples of unmeasured con-
founding include genetic risk factors; secondary causes, such
as primary aldosteronism, renal artery stenosis, and sleep
apnea; and lifestyle factors, such as physical fitness, sodium,
potassium, and alcohol intake.110 Moreover, adjustment for
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antihypertensive medications controlling BP was inconsistent,
as was inclusion and adjustment for clinical strokes. The
absence of sufficient published data for incident CSVD and
CSVD progression indicates that the direction of the associ-
ation between BPV and CSVD cannot be determined. More
specifically, it is possible that higher BPV is merely a
consequence of CSVD, rather than a causative risk factor,
as others have noted.111 In support, mean systolic and
diastolic BP, but not BPV, was associated with incident CSVD
herein, although only ≤3 studies analyzed incident CSVD.
Another limitation of this systematic review is that the
reporting in the retrieved studies precluded an adequately
powered investigation of CSVD subtypes apart from WMH.
Less information was available for other CSVD subtypes
suspected to result from hypertensive vasculopathy, including
deep and infratentorial CMBs112 and EPVSs in the basal
ganglia.113 Moreover, we did not include atrophy or brain
volume because of their diffuse and sometimes nonischemic
causative pathways that are inconsistently reported in
epidemiological studies.7 The sparse evidence for CSVD
subtypes is partly related to discrepant terminology and brain
image interpretation, acquisition, and reporting in the litera-
ture.7 Moreover, evidence suggests that WMH and LPVO
increase the risk for CMBs pointing to overlap in CSVD burden
and potential shared risk factors.1,2 Close investigation of BPV
in relation to CSVD subtypes could be an important area of
investigation as a prior meta-analysis suggests a cumulative
effect for increasing number of CSVD markers on stroke
outcome.8 Moreover, the meta-regression pointed to an
association between tesla size and CSVD, and studies
adopting CT are unable to detect CMBs and EPVSs. We
opted to include these predominantly case-control studies (in
primary outcome 2) as their exclusion would lead to upward
bias in the pooled results for diastolic BPV. Moreover, access
to and use of MRI technology is far from universal, affected by
factors such as rural location, patient health insurance, MRI
contraindications, and the preference for cheaper neuroimag-
ing techniques.114,115
In conclusion, higher systolic BPV was associated with
higher odds for CSVD, and the BPV means were generally
higher among populations with CSVD compared with their
counterparts without CSVD. Collectively, the extant BPV
literature suggests that the magnitude of association between
systolic BPV and CSVD is similar to that reported for mean BP,
indicating BPV may contribute independent information and
variance to the association with CSVD. Evidence was sparse
in relation to diastolic BPV and CSVD subtypes apart from
WMH, where it was found that BPV was associated with
periventricular WMH especially. Given that these findings
cannot rule out that high BPV is a consequence of CSVD,
additional large RCTs as well as prospective cohort studies
with ABPM, investigating CSVD subtypes with 3-T MRI, would
strengthen the evidence base on whether BPV increases
CSVD risk. Given the heterogeneity and suspicion of publica-
tion bias in primary outcome 1, an individual participant data
meta-analysis of BP data sets might help answer important
questions on hypertensive vasculopathy attributable to BPV in
specific CSVD subtypes that are lesser reported, including
infratentorial CMBs112 and EPVSs in the basal ganglia.113
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Data S1. 
In the study by Aribisala et al.1 BPV data were extracted for WMH from the online supplement, Table 
S2 (wave 1). Because the β value = 0.00 for systolic BPV’s association with WMH could not be 
transformed under the method outlined by Peterson and Brown2 and analyses imputed β = 0.050, which 
converts to r = .099. The same imputation method was applied to White et al.3, and the results used to 
impute r values for Shimada et al.4. Data for SBP and DBP were extracted from Table 3 (wave 1). 
In the study by Brickman et al.5 mean and SD values for BPV were calculated from SBP and DBP 
[BP=(1/3 x systolic BP [SBP]) + (2/3 x diastolic BP [DBP]), thus the coefficient (β converted to r) 
reported for the association between BPV with WMH is equivalent for SBPV and DBPV. Brickman et 
al.5 reported WMH analyses using a reference group of persons with low blood pressure and low 
variability (n=176; lower mean BP (<96.48 mmHg and lower fluctuation SD <7.21 mmHg. In our BPV 
analyses, the comparison group was group 3 (n=167; higher mean BP >96.48 mmHg and lower 
fluctuation SD <7.21 mmHg). The effect of BPV on WMH in our analyses used group 4 (n=177, higher 
mean BP >96.48 mmHg and higher fluctuation SD >7.21 mmHg). Hence, the sample sizes reported in 
our r analyses use different totals for BPV (353) and mean BP (343). This study also reported cerebral 
infarctions with no upper size limit and this data was ineligible for LPVO analyses. For diastolic BPV, 
the SD was assumed as 5.39 and not 53.90 as reported in Table 1 pg. 566. 
The study by Duan et al.6 was included as the study referred to incident lacunar infarctions as an 
outcome, and that participants “had no clinical evidence of a variety of acute attacks” pg. 1094. This 
was confirmed in correspondence with the study author, however, the CSVD outcome was not rated as 
incident as no baseline MRI was obtained. For the association between systolic BPV (SD method) and 
CSVD, we assumed a ratio of 1526 participants as 11:1 (pg. 1096) for the low versus high systolic BP 
variation yielding 803 vs. 73 persons in these groups, and rates of infarction at 31.2 and 34.7% 
respectively (panel b, Fig 2). For comparisons between persons with and without CSVD (table 3 & 5), 
we prioritized the SD data as this was the most common method reported by other studies.   
In the study by Filomena7 between group BPV variables were reported by any CSVD.  For comparisons 
between persons with and without CSVD (table 2), only inter-quartile range was reported necessitating 
calculation of SMD from t and p values. We prioritized the SD data as this was the most common 
method reported by other studies and report other variability metrics in ancillary analyses. Though the 
authors reported % CSVD in ARV groups stratified by optimal BP control (Figure S3 A-C), the n for 
each group was not reported.  
In the study by Goldstein et al.8 BPV differences between WMH groups compared the mild/moderate 
WMH insuluar subcortex group (n=52) to those with no WMH in the insuluar subcortex (n=37) because 
of the larger n (compared to total WMH volumes). We prioritized wake measures for mean and BPV to 
ensure parity. In their follow-up study9 the OR for WMH from wake systolic BPV was reported as; OR 
= 1.222 (95% CI 1.060 to 1.409, p = 0.01) in Table 5. Mean wake measures were extracted for SBP to 
provide comparison to wake-variability. In the original study the SBP OR was reported as 1.046 (95% 
CI 1.008 to 1.006, p = .02). When applying the lnOR we imputed the upper CI as 1.085 and standardized 
to a 10mmHg increase in SBP.  
In the study by Gunstad10 unadjusted r data were extracted from Table 2 for mean and variability in 
SBP and DBP (SD method) and we were unable to locate the CV data reported in the method section.  
In the study by Havlik et al.11 we used the total sample size (n=575) for mean BP and a sample size of 
230 (high and low quintile) for BPV.  
In the study by Kario et al.12 the authors provided the M ± SD data upon request, comparing patients 
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In the study by Kukla et al.13 we considered the absence of previous stroke (past 6 months) as 
justification for inclusion given that the CSVD marker was silent lacunae (<15 mm), and the control 
group were without lacunae. As only M (IQR) were reported for BP, we generated t-statistics from the 
p values reported in Table 1. Circadian variability (percent change between day vs. night) was not 
considered a BPV metric and thus OR in Figure 1 & 2 were not extracted.  
In the study by Leung et al.14 the authors reported incident covert brain infarction and also worsening 
white matter grade with sensitivity analyses including persons with baseline cardiovascular risk factors. 
We prioritized the white matter outcome in our primary analysis inclusive of persons with baseline 
cardiovascular risk factors (larger n) depicted in Table 4 with values reported in RR. The RR values for 
10mmHg increase in diastolic BP and BPV were standardized to a 5 mmHg increase to remain 
consistent with other studies. Systolic values were presented in standardized 10mmHg increase format. 
Correlations with WMH were obtained from supplement table III and incident CSVD utilized 
worsening white matter grade from Table 2.  
In the study by Liu et al.15 WMH volumes % change were illustrated in figures and exact values were 
not reported. Descriptive data was estimated from the % change (panel a) as this data produced a t-
value for conversion to r. Based on the total values depicted for a sample of 232 persons, the WMH 
volume % change was estimated from Fig 3a as; high tertile of CV (n = 77) M = 18 ± 11; lowest tertile 
of CV (n = 77), M = 11 ± 10, yielding t(153) = 4.13, p <.001. For periventricular WMH volumes % 
change reported in Fig 5 (panel a pg. 250) estimated values were; high tertile of CV (n = 77) M 20 ± 
11; and lowest tertile of CV (n = 77), M = 12.5 ± 11, yielding t(153) = 4.23, p <.001. For deep WMH 
volumes % change reported in Fig 6 (panel a pg. 251) estimated values were; high tertile of CV (n = 
77) M 12.0 ± 12, and lowest tertile of CV (n = 77), M = 8.0 ± 11, yielding t(153) = 2.164, p .033.
In the study by McNeil et al.16 the association between BPV and WMH volumes were extracted from 
Model 2 in Table 2 for parity in adjustment of covariates with beta values reported for mean pressure.  
In the study by Sabayan et al.17 the authors reported relevant data for WMH, CMB, and cerebral 
infarctions (cortical and lacunar). As the size of lacunar infarctions was not specified18 we prioritized 
CMB reported as OR (95% CI) in primary outcome analyses. The OR for mean BP and CMB was 
extracted from the “high BP” group, Table S6. Differences between BPV groups on WMH volumes 
were calculated from the M (SE) reported in Table 4 for high versus low BPV tertiles (n=137 and n=207 
respectively).  Data for mean BP were extracted from Table S6 for high versus low average BP (n=225 
and n=151 respectively).   
In the study by Sander et al.19 we extracted WMH data from the multivariate regression model (Table 
2) and converted β to r as data was available for systolic and diastolic mean and variability metrics.
Circadian variability was not considered.
In the study of Shimada et al.4 where a non-significant correlation was reported for BPV and 
periventricular WMH (with data not shown), a small correlation coefficient of r = .10 was imputed for 
systolic BPV in order to include this study in the pooled analyses (the effect size was based on the 
imputation results of Aribisala et al.1). Differences in diastolic BP between severity of periventricular 
WMH grade (I to III) was reported as p = .09 but insufficient data was available to impute an effect 
size, as only mean BP was presented in Figure 5.  
In the study by Sierra et al.20 day and night variability, quantified as Δ nocturnal fall, was ineligible for 
inclusion. Only the SD from ABPM was extracted.  
In the study by Tartaro et al.20 data extraction prioritized daytime measures for the SD method (most 
common method).  
In the study by Tohgi et al.21 data were extracted from the population who were treated with 
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infarction population was highest, and the non-treated sample was above the 50% threshold for previous 
stoke. The definition of recent small subcortical infarction or lacunae was not specified but described 
elsewhere.22 
In the study by Tsukishima et al.23 the largest CSVD group data was persons with silent infarction but 
free from WML (n=35). As the SD or SE values or t-statistics were not reported the SDs were imputed 
utilizing total group data reported in Table 2 pg. 191.  
In the study by Tully et al.24 additional analyses were performed for between group comparisons in 
BPV (CV method) according to extensive WMH. The definition of extensive WMH was derived from 
equal or above sex-specific upper quartiles within the cohort at baseline MRI; men (7.39 cm3), women 
(5.73 cm3)25. Logistic regression for extensive WMH adjusted for age and sex and were standardized to 
10/5mmHg increase. Correlations with WMH were performed unadjusted utilizing the CV metric of 
BPV.  
In the study by White et al.3 a non-significant association was reported “various systolic BP variability 
measures (the SD of the 24-hour mean systolic BP, awake systolic BP, or sleep systolic BP) were not 
associated with WMH or functional parameters.” We imputed a non-significant association between 
systolic BPV (SD method) and WMH as β = .050 as was applied to Aribisala et al.1. Two sample sizes 
were reported; 77 (31 males + 46 females, Table 1) and 72 in the eligible sample. We used the smaller 
conservative sample size.    
In the dissertation by Xie 26 SMDs were extracted for persons with and without CMB as this was the 
CSVD sub-type with the highest N (Table 8.2) and SMDs were extracted from Table 6.5. The OR for 
CSVD were extracted for severe periventricular WMH for the main endpoint analysis (Table 8.6 – SD 
method; mean BP extracted from Table 6.9 SBP only). CV data are also shown here in our ancillary 
analysis. BPV data for CMBs was only reported using pulse pressure metrics and not systolic or 
diastolic BPV. The periventricular odds ratios were used to calculate d. The Spearman’s rho correlations 
with WMH reported in Table 8.8 were deemed unsuitable for pooling.  
In the study by Yamaguchi27 the systolic CV [Table 3, total sample] was prioritized over the SD values 
for CSVD progression, as the systolic CV was presented in a multivariable adjusted model. The diastolic 
BPV analyses for CSVD progression also utilized CV to remain consistent (adjusted, model 2). Analysis 
of CSVD progression was restricted to the sample with CSVD (n=174) and adjusted CV-BPV analysis.  
In the study by Yang et al.28 the association between BPV with CSVD was available for EPVS in basal 
ganglia (Table 4, pg. 9) but not EPVS in the white matter. We extracted CV data (24-hours) as this data 
was available for systolic and diastolic BPV. For between group differences we compared EPVS in the 
basal ganglia (grade 3 versus 1), estimating the Mean from Fig 1 pg. 7 to calculate a t-statistic and SMD 
based on the reported p value (only median and IQR values were reported in Table 3).  
In the study by Yang et al.29  data total CSVD burden was extracted from Table 3 (Model 2) and the 
rationale was that both mean and BPV metrics were reported in this adjusted model. Data extracted 
for our primary analysis was for the SD method (CV and weighted SD also shown in our ancillary 
analysis). For comparative purposes with mean SBP, the ancillary analyses extracted data from Model 
2 (including day vs. night effect sizes). For comparison of M ± SD, we selected the group with 1 
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Table S1. PRISMA checklist 
Section/topic # Checklist item 
Reported 
on page # 
TITLE 
Title 1 Identify the report as a systematic review, meta-analysis, or both. 1 
ABSTRACT 
Structured summary 2 Provide a structured summary including, as applicable: background; 
objectives; data sources; study eligibility criteria, participants, and 
interventions; study appraisal and synthesis methods; results; limitations; 




Rationale 3 Describe the rationale for the review in the context of what is already 
known.  
5-6
Objectives 4 Provide an explicit statement of questions being addressed with reference 




Protocol and registration 5 Indicate if a review protocol exists, if and where it can be accessed (e.g., 
Web address), and, if available, provide registration information including 
registration number.  
S1 
Eligibility criteria 6 Specify study characteristics (e.g., PICOS, length of follow-up) and report 
characteristics (e.g., years considered, language, publication status) used 
as criteria for eligibility, giving rationale.  
S1 
Information sources 7 Describe all information sources (e.g., databases with dates of coverage, 
contact with study authors to identify additional studies) in the search and 
date last searched.  
S1 
Search 8 Present full electronic search strategy for at least one database, including 
any limits used, such that it could be repeated.  
S3 
Study selection 9 State the process for selecting studies (i.e., screening, eligibility, included in 
systematic review, and, if applicable, included in the meta-analysis).  
S1 
Data collection process 10 Describe method of data extraction from reports (e.g., piloted forms, 
independently, in duplicate) and any processes for obtaining and confirming 
data from investigators.  
S1 
Data items 11 List and define all variables for which data were sought (e.g., PICOS, 
funding sources) and any assumptions and simplifications made.  
S1 
Risk of bias in individual 
studies  
12 Describe methods used for assessing risk of bias of individual studies 
(including specification of whether this was done at the study or outcome 
level), and how this information is to be used in any data synthesis.  
S1 
Summary measures 13 State the principal summary measures (e.g., risk ratio, difference in means). S1 
Synthesis of results 14 Describe the methods of handling data and combining results of studies, if 
done, including measures of consistency (e.g., I2) for each meta-analysis. 
S1 
Risk of bias across 
studies  
15 Specify any assessment of risk of bias that may affect the cumulative 
evidence (e.g., publication bias, selective reporting within studies).  
S1 
Additional analyses 16 Describe methods of additional analyses (e.g., sensitivity or subgroup 
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Section/topic # Checklist item 
Reported 
on page # 
RESULTS 
Study selection 17 Give numbers of studies screened, assessed for eligibility, and included in 




Study characteristics 18 For each study, present characteristics for which data were extracted (e.g., 
study size, PICOS, follow-up period) and provide the citations.  
S6, S7, 
S8 
Risk of bias within 
studies  
19 Present data on risk of bias of each study and, if available, any outcome 
level assessment (see item 12).  
S9 
Results of individual 
studies  
20 For all outcomes considered (benefits or harms), present, for each study: 
(a) simple summary data for each intervention group (b) effect estimates
and confidence intervals, ideally with a forest plot.
7-8, Fig
1-4
Synthesis of results 21 Present results of each meta-analysis done, including confidence intervals 
and measures of consistency.  
7-8, Fig
1-4
Risk of bias across 
studies  
22 Present results of any assessment of risk of bias across studies (see Item 
15).  
S11 
Additional analysis 23 Give results of additional analyses, if done (e.g., sensitivity or subgroup 





Summary of evidence 24 Summarize the main findings including the strength of evidence for each 
main outcome; consider their relevance to key groups (e.g., healthcare 
providers, users, and policy makers).  
9,10 S12 
Limitations 25 Discuss limitations at study and outcome level (e.g., risk of bias), and at 
review-level (e.g., incomplete retrieval of identified research, reporting bias). 
11-12
Conclusions 26 Provide a general interpretation of the results in the context of other 
evidence, and implications for future research.  
12-13
FUNDING 
Funding 27 Describe sources of funding for the systematic review and other support 
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Table S2. Electronic Search String by Database 
 MEDLINE EMBASE SCOPUS 
 ("blood pressure variability" OR "average real 
variability" OR "variance independent of the mean" 
OR "blood pressure oscillation*" OR "blood 
pressure fluctuation*" OR “blood pressure 
monitoring, ambulatory” [MeSH])  
('blood pressure variability':ti,ab,kw OR 'average 
real variability':ti,ab,kw OR 'variance independent 
of the mean':ti,ab,kw OR 'blood pressure 
oscillation':ti,ab,kw OR 'blood pressure 
fluctuation':ti,ab,kw OR 'ambulatory blood 
pressure monitoring':ti,ab,kw) 
(TITLE-ABS-KEY ("blood pressure variability"  
OR  "average real variability"  OR  "variance 
independent of the mean"  OR  "blood pressure 
oscillation*"  OR  "blood pressure fluctuation*"  
OR  "ambulatory blood pressure monitoring") )  
AND  
("cerebral small vessel disease*" OR lacun* 
"subcortical infarct*" OR “subcortical stroke” OR 
microinfarct* OR “subcortical lesion” OR 
cerebrovascular disorder [MeSH]) OR "perivascular 
space*" OR "Virchow-Robin space*"  OR 
leukoaraiosis OR "white matter lesion*" OR "white 
matter hyperintens*" OR "cerebral microbleed*" 
OR “micro haemorrhag*”) 
AND 'cerebrovascular disease':ti,ab,kw OR 
'lacunes':ti,ab,kw OR 'subcortical 
infarction':ti,ab,kw OR 'subcortical 
stroke':ti,ab,kw OR 'microinfarct':ti,ab,kw OR 
'subcortical lesion':ti,ab,kw OR 'cerebrovascular 
disorder':ti,ab,kw OR 'enlarged perivascular 
spaces':ti,ab,kw OR 'virchow-robin space':ti,ab,kw 
OR 'leukoaraiosis':ti,ab,kw OR 'white matter 
lesion':ti,ab,kw OR 'white matter 
hyperintensity':ti,ab,kw OR 'white matter 
hyperintensities':ti,ab,kw OR 'cerebral 
microbleed':ti,ab,kw OR 'micro 
haemorrhage':ti,ab,kw 
AND  
(TITLE-ABS-KEY ( "cerebral small vessel 
disease*"  OR  lacun*  "subcortical infarct*"  OR  
"subcortical stroke"  OR  microinfarct*  OR  
"subcortical lesion"  OR  "cerebrovascular 
disorder"  OR  "perivascular space*"  OR  
"Virchow-Robin space*"  OR  leukoaraiosis OR  
"white matter lesion*"  OR  "white matter 
hyperintens*"  OR  "cerebral microbleed*"  OR  
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Classification Reason for exclusion 
30, 31 NC Acute stroke BP and BPV were quantified during the acute stage of hospital admission for stroke (i.e. <24 
hours).   
32 No No BPV BPV was not quantified, only 5mmHg increases or decreases in systolic and diastolic BP were 
evaluated in relation to WMH.   
33 NC Acute stroke BPV was quantified during the in-patient stay and sub-acute period of lacunar infarction (i.e. 1-
14 days).  
34 Yes No BPV BPV was not quantified. Only dipping variability patterns were reported. 
35 NC Dementia BPV and leukoaraiosis were analyzed in a mixed neurological sample, most (64%) with 
dementia.  
36 No CSVD ineligible BPV was analyzed in relation to white matter integrity, quantified with fractional anisotropy. No 
marker of CSVD was reported according to this reviews definitions.   
37-39 Yes Duplicate The collection of studies were reported as having overlapping samples in Kario et al.12, 39. No 
BPV data were reported in two studies37, 38. The authors supplied additional information for this 
meta-analysis.  
40 Yes No control group There was no reference group without CSVD in the sample, stratified by nocturnal dipping status 
from ABPM.  
41 NC Acute stroke 24-hour ABPM was quantified during the sub-acute stage of lacunar infarction (i.e. 2-4 weeks). 
Only dipping status was reported in relation to CSVD.  










Classification Reason for exclusion 
43 NC No BPV Though CSVD was quantified, there was an insufficient amount of BP measures to calculate 
BPV. 
44 NC Acute stroke BPV measured during acute stage of intracerebral hemorrhage. 
45 NC Dementia A visual rating of WMH was obtained in hospitalised lacunar stroke patients and the control 
group were patients with Binswager’s disease.  
46, 47 NC Above 50% stroke 
prevalence threshold 
The entire sample had a previous stroke in the Cilostazol versus Aspirin for Secondary Ischemic 
Stroke Prevention RCT.  
48 Yes Duplicate Contact author confirmed this was an overlapping sample with 49 which has a larger sample. 
50 NC No BPV This study underwent full-text review as it was cited as evidence for a lack of association 
between WMH and BPV in1. However, no BPV data was presented, only mean pressure (per SD 
increase).   
51 No Duplicate Duplicate sample reporting BPV by male and female sex, overlapping the included cross-
sectional 8and longitudinal data 9. 
52 NC No BPV No measures of BPV were reported in relation to white matter microstructure. 
53 No No CSVD No CSVD outcome included in macrovascular endpoint. 
54 No No CSVD No CSVD outcome in incident endpoint. 
ABPM, ambulatory blood pressure monitoring; BP, blood pressure; BPV, blood pressure variability; CSVD, cerebral small vessel disease; NC, not 
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Table S4. Descriptive Characteristics of Included Studies 
Study reference Country Cohort name Study 
design 
N Age M yrs ± 











Aribissala 20141 UK Lothian Birth Cohort Cohort 694 72.6 ± 0.7 47 491 72 27.98 
Brickman 20105 USA Washington Heights-
Inwood Columbia Aging 
Project 
Cohort 686 ≥65, 
approximately 
79 
68 66 312 NR 
Duan 20096 CHI NR Cross-
sectional 
1526 60-98 0 78 NR NR 
Filomena 20157 ESP Investigating Silent 
Strokes in Hypertensives 
Cohort 487 49-67 47 95 0.0 29.8 





144 66.2 ± 6.0 57 101 NR 24.6 
Gunstad 200510 USA NR Cohort 39 71.4 ± 7.4 33 771 0.0 NR 
Havlik 200211 USA Honolulu-Asia Aging 
Study 
Cohort 575 81.6 ± 5.0 0 23 12 NR 
Kario 200312 JAP NR Cohort 532 72 64 55 0.0 24.2 
Kukla 199813 GER NR Case-
control 
118 70 41.5 45 0.0 NR 
Leung 201714 USA Cardiovascular Health 
Study  
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Study reference Country Cohort name Study 
design 
N Age M yrs ± 











Liu 201647 CHI NR Cohort 232 84.4 ± 2.5 75 51 0.0 23.5 
McNeil 201816 UK Aberdeen Birth Cohort Cohort 227 64.5 ± 0.81 52 45 NR NR 
Nakanishi 201955 USA Cardiovascular 
Abnormalities 
and Brain Lesions study 
Cross-
sectional 
828 70.9 ± 9.0 60.1 78.5 0.0 28.3 
Sabayan 201317 NL, UK PROspective Study of 
Pravastatin in the 
Elderly at Risk 
RCT 553 74.9 ± 3.2 44 631 16 26.7 
Sander 200019 GER NR Case-
control 
227 62-70 49 441 NR NR 
Shimada 19904 JAP NR Case-
control 
73 70 ± 6 67 21 0.0 NR 
Sierra 200249 ESP NR Case-
control 
66 50-60 38 100 0.0 29.1 
Tartaro 199920 ITA NR Cross-
sectional 
66 77 52 231 0.0 NR 
Tohgi 199121 JAP NR Case-
control 
25 69 ± 10 52 100 40 NR 
Tsukishima 200123 JAP NR Cohort 300 72.9 ± 3.9 52 381 0.0 NR 
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Study reference Country Cohort name Study 
design 
N Age M yrs ± 











White 20113 USA NR Cohort 72 82.1 ± 3.9 60 64 0.0 26.3 
Xie 201526 CHI NR Cross-
sectional 
349 71.9 ± 5.2 45 100 0.0 24.9 
Yamaguchi 201427 JAP NR Cohort 210 70.9 ±  0.9 55 41 30 24.2 
Yang 201728 CHI NR Cross-
sectional 
573 69 (55-81) 38 60 0.0 25.6 
Yang 201829 CHI NR Cross-
sectional 
251 68 47 59 0.0 25.2 
CHI, China; ESP, Spain; FRA, France; GER, Germany; ITA, Italy; JAP, Japan; MS, morning surge; NL, The Netherlands; NR, not reported; UK, United 
Kingdom; USA, United States of America;  
1. Prevalence of hypertension if antihypertensive drug treatment was not reported
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Table S5. Blood Pressure Monitoring Characteristics of Included Studies 















Aribissala 20141 705IT (Omron Corp), 
oscillometric 
Single clinic 
visit (6 readings; 
3 sitting, 3 
standing) 
NR NR (2 waves 3 
yrs apart) 
No NA SD, CV, ARV, 
SV, (only CV 
presented)  
No 
Brickman 20105 Dinamap 
Pro 100 (Critikon Co), 
oscillometric 
Clinic visit-to-
visit (3 readings; 
over 9 minutes) 
1-2 years 6-8 yrs No NA SD No 
Duan 20096 90217 (Spacelabs), 
oscillometric 
ABPM 30 mins (day) 60 
mins (night) 





NR SD, wSD, SD' Yes 
Filomena 20157 90217-5Q (Spacelabs), 
oscillometric 
ABPM 20 mins (day) 30 
mins (night) - 24 
hours  
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ABPM 20 mins (day) 60 
mins (night) - 24 
hr ABPM 
repeated at 5 yrs 









SD (CV NR) Yes 





visit (8 readings) 
10 mins 2 hrs No NA SD (CV NR) No 




visit (2 to 3 
readings) 
2-3 yrs 6 yrs No NA VIR No 
Kario 200312 ABPM-630 (Nippon 
Colin Co) or TM-2421 
or TM-2425 (A&D 
Co), oscillometric 
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Kukla 199813 ABD-90217 
(Spacelabs), 
oscillometric 






















visit (3 readings, 
2 used for BPV) 
1 yr 4 yrs No NA SD, VIR No 




morning and 2 
evening 
readings) 
2 mins (morning 
and night) 
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McNeil 201816 Omicron (NR), 
oscillometric 
Clinic visit-to-
visit (3 readings) 
2 yrs 4 yrs No NA CV No 
Nakanishi 201955 90217 (Spacelabs), 
oscillometric 
ABPM 15 mins (day) 30 
mins (night) - 24 
hours 









< 0.90 (35.9) 
CV No 




3 mth 3.2 yrs No NA SD No 
Sander 200019 ABD-90217 
(Spacelabs), 
oscillometric 
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Shimada 19904 ABPM-630 (Nippon 
Kohrin Co), 
oscillometric 





NR SD No 
Sierra 200249 90217 (Spacelabs), 
oscillometric 











Tartaro 199920 90217 (Spacelabs), 
oscillometric 
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Tohgi 199121 ABPM-630 (Colin 
Medical), 
oscillometric 



















NR 10 yrs No NA CV Yes 
Tully 201824 M4 (Omron), 
oscillometric 
Clinic visit-to-
visit (3 readings) 
2 mins 4 yrs No NA CV Yes 
White 20113 Oscar II (Suntech), 
oscillometric 
ABPM 15 mins (day) 30 
mins (night) 
















10-15 mins every 
14 weeks 
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ABPM 30 mins (day) 60 
mins (night) 





NR SD, wSD, CV, 
ARV 
Yes 
Yang 201728 FB-250 (Fukuda 
Denshi), oscillometric 
ABPM 30 mins (day) 60 
mins (night) 





NR SD, CV Yes 
Yang 201829 TM-2430 (A&D), 
oscillometric 
ABPM 30 mins (day) 60 
mins (night) 





NR SD, wSD, CV Yes 
ABPM, ambulatory blood pressure monitoring; ARV, average real variability; CMB, cerebral microbleed; CV, coefficient of variation; CSVD, cerebral small 
vessel disease; EPVS, enlarged perivascular space; LPVO, lacunae of presumed vascular origin; MV, maximal variation; NA, not applicable; NR, not reported; 
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variation; VIM, variance independent of the mean; VIR, variance in residuals; WMH, white matter hyperintensity; WML, white matter lesion detected on 
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Table S6. Imaging methods for CSVD in the Included Studies 
Study reference CSVD sub-types quantified and 


















Aribissala 20141 WMH (visual rating on Fazekas 
scale) 
694 694 MRI 1.5 T1, T2 NR T2*- FLAIR NR NRb 
Brickman 20105 WMH (volumetry), BI (>3 mm) 686 686 MRI 1.5 T1, T2 NR NR FLAIR NR 0.73-
0.90 
Duan 20096 LPVO (2-15 mm) 1526 NR MRI NR NR NR NR NR NR NR 
Filomena 20157 Combined endpoint of WMH 
(visual rating on Fazekas) & 
LPVO (3-20 mm) 
487 487 MRI 1.5 T1, T2 Yes NR FLAIR NR NR 
Goldstein 19988 &  
20059 
WMH (visual rating) 144 144 MRI 1.5 NR NR NR NR NR NR 
Gunstad 200510 WMH (volumetry) 39 39 MRI 1.5 T1, T2 NR NR FLAIR NR >0.90
Havlik 200211 WMH (visual rating) 575 575 MRI 1.5 T2 Yes NR PD NR NR 
Kario 200312 LPVO (3-15 mm) 519 519 MRI 1.5 T1, T2 NR NR NR NR 0.70-
0.00 
Kukla 199813 LPVO (<15 mm) 188 33 MRI & 
CT 
1.5 T2 NR NR PD NR NRb 
Leung 201714 WMH (visual rating) 1844 1844 MRI 1.5 T1, T2 NR NR NR NR NR 
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Study reference CSVD sub-types quantified and 


















McNeil 201816 WMH (volumetry & visual rating 
on Schelten’s scale) 
227 227 MRI 1.5 T1, T2 NR NR FLAIR NR NRc 
Nakanishi 55 WMH (volumetry), LPVO (> 
3mm) 
828 828 MRI 1.5 T2 NR NR FLAIR NR NR 
Sabayan 201317 WMH (volumetry), LPVO, BI 
(size NR), CMB (size NR) 
553 553 MRI 1.5 T2 Yes NR FLAIR NR NR 
Sander 200019 WMH (volumetry & visual rating) 227 227 MRI 1 T1, T2 NR NR PD NR NR 
Shimada 19904 WMH (visual rating), LPVO (<10 
mm) 
73 73 MRI 0.5 T1, T2 NR NR NR NR NRb
Sierra 200249 WMH (visual rating) 66 66 MRI 1.5 T1, T2 NR NR PD NR NR 
Tartaro 199920 WMH (visual rating) 66 - CT NA NA NA NA NA NA NR 
Tohgi 199121 RSSCI (size NR), LPVO (size 
NR) 
31 - CT NA NA NA NA NA NA NA 
Tsukishima 200123 WMH (visual rating), LPVO (size 
NR)  
300 - CT NA NA NA NA NA NA 0.92 
Tully 201824 WMH (volumetry) 1612 1612 MRI 1.5 T1, T2 NR NR NR NR NRc
White 20113 WMH (volumetry) 72 72 MRI 3 T1, T2 NR NR FLAIR NR NRc 
Xie 201526 WMH (volumetry and visual 
rating on Fazekas scale), CMB (2-
10 mm, BOMBS), BI (>3 mm)  
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Study reference CSVD sub-types quantified and 


















Yamaguchi 201427 WMH (volumetry & visual rating 
on Fazekas scale),  LPVO (3-15 
mm) 
210 210 MRI 0.5 T1, T2 NR NR FLAIR NR 0.86 & 
0.68 
Yang 201728 EPVS (<3 mm; visual grading 
basal ganglia and white matter) 
573 573 MRI 3 T1, T2 NR NR FLAIR NR ≥.80 
Yang 201829 Combined endpoint of WMH 
(Fazekas scale), CMB (size NR), 
LPVO (3-20 mm), EPVS (< 3 
mm; basal ganglia), atrophya
251 251 MRI 3 T1, T2 NR SWI FLAIR NR ≥0.70 
a. Atrophy included in comparison between CSVD groups on M ± SD BPV
b. Single-rater
c. Volumetry only
BI, brain infarcts; BOMBS, Brain Observer MicroBleed Scale; CMB, cerebral microbleed; CT, computed tomography; DTI, diffusion tensor imaging; DWI, 
diffusion weighted imaging; EPVS, enlarged perivascular space; FLAIR, fluid-attenuated inversion recovery; GRE, gradient recalled echo; LPVO, lacune of 
presumed vascular origin; MRI, magnetic resonance imaging; NA, not applicable; NR, not reported; PD, proton density; RSSCI, recent small sub-cortical 
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Prosp No CD CD NA Yes Medium  Yes NA NA No CD CD Yes 
Brickman 
20105 
Prosp No CD CD NA Yes High Yes Yes Yes Yes CD CD Yes 
Duan 20096 Retro No CD CD NA Yes Low Partial CD No No CD CD CD 
Filomena 
20157 
Prosp Partial CD CD CD Yes High Yes Yes Yes Yes CD Yes Yes 
Goldstein 
19988 &  
20059 
Prosp Yes Yes Yes NA No High Yes Yes No No CD Yes Yes 
Gunstad 
200510 
Prosp Yes CD CD NA No Medium Yes NA No No CD CD Yes 
Havlik 
200211 
Prosp Yes CD CD NA Yes Medium Yes NA Yes No CD Yes Yes 
Kario 
200312
Prosp Yes Yes Yes NA Yes High Yes CD CD CD CD Yes Yes 
Kukla 
199813 
Prosp Partial CD Partially Yes No High Yes No No No CD Yes Yes 
Leung 
201714 
Prosp No CD CD NA Yes Low Yes NA Yes Yes CD Yes Yes 
Liu 201647 Prosp Yes CD CD NA Yes Medium Yes Yes Yes Yes CD Yes Yes 
McNeil 
201816 
Prosp No CD CD NA Yes Low Yes NA Yes No CD CD Yes 
Nakanishi 55 Prosp No CD CD NA Yes High Yes Yes Yes Yes CD Yes Yes 
Sabayan 
201317 
Prosp Yes CD Yes Yes Yes Medium Yes Yes Yes No No Yes Yes 
Sander 
200019 
Prosp Yes No CD No Yes High Yes Yes No No CD Yes Yes 
Shimada 
19904 
Prosp Yes CD Yes No No Medium Yes NA No No CD Yes Yes 
Sierra 
200249 
Prosp Yes CD Yes NA Yes High Yes Yes Yes 
(partial) 
No CD Yes Yes 
Tartaro 
199920 





























































Prosp No CD CD CD No High No Yes No No CD Yes Yes 
Tsukishima 
200123 
Prosp Yes CD Yes CD Yes High Yes Yes No Yes CD Yes Yes 
Tully 
201824
Prosp Yes Yes Yes NA Yes Medium Partial Yes Yes No CD Yes Yes 
White 
20113 
Prosp Yes CD CD NA No High Yes NA Yes 
(partial) 
No CD Yes Yes 
Xie 201526 Prosp Yes Yes NA NA Yes High Yes Yes Yes 
(partial) 
No No Yes Yes 
Yamaguchi 
201427 
Prosp No CD CD CD Yes High Yes Yes Yes No No Yes Yes 
Yang 
201728 
Prosp Yes CD NA NA Yes High Yes Yes Yes Yes No Yes Yes 
Yang 
201829 
Prosp Yes CD NA NA Yes High Yes Yes Yes Yes No Yes Yes 
CD, cannot determine; Excl, exclusion; Incl, inclusion; ITT, intention to treat; NA, not applicable; Prosp, prospective; Retro, Retrospective D
ow
nloaded from
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Yes Yes No No NA NA CD Yes CD No Yes Yes Yes 
Brickman 
20105 
Yes Yes Yes Yes CD Yes Yes Partially CD No Yes Yes Yes 
Duan 20096 Yes NA NA NA CD No Yes NA NA No Yes Yes Yes 
Filomena 
20157 
Yes NA NA NA CD Yes CD Partially NA No Yes Yes Yes 
Goldstein 
19988 &  
20059 
Yes Yes Yes No CD No Yes No CD No Yes Yes Yes 
Gunstad 
200510 
Yes NA NA NA NA No CD No NA No Partially Yes Yes 
Havlik 
200211 
Yes Yes Yes No CD Yes CD Yes CD No Yes Yes Yes 
Kario 200312 Yes Yes No No CD CD Yes CD CD No Yes Partially Yes 
Kukla 199813 Yes NA NA NA NA No Yes Partially NA No Yes Yes Yes 
Leung 
201714 
Yes NA NA NA NA Yes CD Yes NA No Yes Yes Yes 
Liu 201647 Yes NA NA NA NA Yes CD Yes NA No Yes Yes Yes 
McNeil 
201816 
Yes NA NA NA NA No CD No NA No Yes Yes Yes 
Nakanishi55 Yes NA NA NA NA Yes Yes Yes NA No Yes Yes Yes 
Sabayan 
201317 
Yes Yes No CD CD Yes CD No CD No Yes Yes Yes 
Sander 
200019 
Yes NA NA NA NA No No No NA No Partially Yes No 
Shimada 
19904 
Yes NA NA NA NA NA CD No NA Yes Partially Yes Yes 
Sierra 200249 Yes NA NA NA NA No CD Partially NA No Partially Yes No 
Tartaro 
199920 






















































Tohgi 199121 Yes NA NA NA NA No CD No NA CD Partially CD Yes 
Tsukishima 
200123 
Yes CD Yes CD CD No CD Partially CD No Partially Yes Yes 
Tully 201824 Yes NA NA NA NA Yes Yes Yes NA CD Partially Yes Yes 
White 20113 Yes Yes No Yes CD NA CD Partially CD No Yes Yes Yes 
Xie 201526 Yes NA NA NA NA No Yes No CD No Yes Yes No 
Yamaguchi 
201427 
Yes Yes No No CD Yes Yes Yes CD No Yes Yes No 
Yang 201728 Yes NA NA NA NA Yes Yes Yes NA No Yes Yes No 
Yang 201829 Yes NA NA NA NA Yes CD Yes NA No Yes Yes Yes 
CD, cannot determine; NA, not applicable;  
Item 26 and 27 dropped as they refer to harms from an intervention. 
Complete List of RTI Items56 
1. Is the study design prospective, retrospective, or mixed?
2. Are critical inclusion/exclusion criteria clearly stated (does not require the reader to infer)?
3. Are the inclusion/exclusion criteria measured using valid and reliable measures?
4. Did the study apply inclusion/exclusion criteria uniformly to all comparison groups/arms of the study?
5. Was the strategy for recruiting participants into the study the same across study groups/arms of the study?
6. Was the sample size sufficiently large to detect a clinically significant difference of 5% or more between groups in at least one primary outcome
measure?
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8. Are the important outcomes pre-specified by the researchers? Do not consider harms in answering this question unless they should have been pre-
specified.
9. Is the selection of the comparison group appropriate, after taking into account feasibility and ethical considerations
10. Any attempt to balance the allocation between the groups (e.g., through stratification, matching, propensity scores).
11. Did researchers isolate the impact from a concurrent intervention or an unintended exposure that might bias results, e.g., through multivariate analysis,
stratification, or subgroup analysis?
12. Did execution of the study vary from the intervention protocol proposed by the investigators and therefore compromise the conclusions of the study?
13. Were the outcome assessors blinded to the intervention or exposure status of participants?
14. Are interventions/exposures assessed using valid and reliable measures, implemented consistently across all study participants?
15. Are outcomes assessed using valid and reliable measures, implemented consistently across all study participants?
16. Is the length of follow-up the same for all groups?
17. Is the length of time following the intervention/exposure sufficient to support the evaluation of primary outcomes and harms?
18. Did attrition from any group exceed 20 percent for <1 year follow-up and 30 percent for > 1 year follow-up?
19. Did attrition from any group exceed [x] percent?
20. Does the analysis control for baseline differences between groups?
21. Are confounding and/or effect modifying variables assessed using valid and reliable measures across all study participants?
22. Were the important confounding and effect modifying variables taken into account in the design and/or analysis (e.g., through matching, stratification,
interaction terms, multivariate analysis, or other statistical adjustment)?
23. In cases of high loss to follow-up (or differential loss to follow-up), is the impact assessed (e.g., through sensitivity analysis or other adjustment
method)?
24. Are any important primary outcomes missing from the results?
25. Are the statistical methods used to assess the primary benefit outcomes appropriate to the data?
26. Are any important harms or adverse events that may be a consequence of the intervention/exposure missing from the results?
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28. Are results believable taking study limitations into consideration?
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Table S8. Meta-Regression Results for Primary Outcomes 
Outcome Variable Point Estimate (95% CI) SE Q (df) P 
Odds for CSVD 
Systolic BPV Age 0.02 (0.01 to 0.02) 0.01 25.86 (1) <0.001 
Female sex 0.01 (-.01 to 0.01) 0.01 0.99 (1) 0.32 
Antihypertensive or hypertension -0.00 (-0.00 to 0.00) 0.00 16.23 (1) <0.001 
Dipping NA - - - 
Stroke 0.02 (0.01 to 0.03) 0.01 6.73 (1) 0.009 
Body mass index kg/m2 -0.06 (-0.08 to -0.05) 0.01 51.64 (1) <0.001 
Tesla of MRI 0.17 (0.11 to 0.22) 0.03 41.27 (1) <0.001 
Diastolic BPV Age -0.06 (-0.12 to -0.01) 0.03 3.91 (1) 0.047 
Female sex -0.01 (-0.02 to 0.00) 0.00 2.29 (1) 0.13 
Antihypertensive or hypertension 0.00 (-0.01 to 0.01) 0.00 0.34 (1) 0.56 
Dipping  NA - - - 
Stroke 0.02 (0.00 to 0.04) 0.01 5.00 (1) 0.025 
Body mass index kg/m2 -0.06 (-0.15 to 0.03) 0.05 1.75 (1) 0.19 
Tesla of MRI -0.01 (-0.14 to 0.13) 0.07 0.01 (1) 0.92 
SMD in BPV 
Systolic BPV Age -0.03 (-0.06 to -0.01) 0.02 4.03 (1) 0.045 
Female sex 0.01 (-.01 to 0.00) 0.00 1.23 (1) 0.27 
Antihypertensive or hypertension -0.00 (-0.01 to 0.01) 0.00 2.38 (1) 0.12 
Dipping NA - - - 
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Outcome Variable Point Estimate (95% CI) SE Q (df) P 
Body mass index kg/m2 -0.04 (-0.09 to 0.01) 0.02 3.73 (1) 0.053 
Tesla of MRI 0.03 (-0.03 to 0.08) 0.03 0.96 (1) 0.33 
Diastolic BPV Age 0.01 (-0.02 to 0.04) 0.02 0.23 (1) 0.63 
Female sex 0.00 (0.00 to 0.01) 0.00 4.99 (1) 0.025 
Antihypertensive or hypertension 0.00 (-0.00 to 0.01) 0.00 0.15 (1) 0.69 
Dipping NA - - - 
Stroke 0.00 (-0.01 to 0.01) 0.01 0.03 (1) 0.87 
Body mass index kg/m2 -0.03 (-0.09 to 0.04) 0.03 0.66 (1) 0.42 
Tesla of MRI 0.05 (-0.00 to 0.11) 0.03 3.49 (1) 0.061 
For SMDs, Tesla of MRI was coded 0 for CT scans and in the study by Duan where T was not reported.   
Significant values in bold  
Dipping data reported in 3 or fewer studies 
ABPM, ambulatory blood pressure monitoring; BP, blood pressure; BPV, blood pressure variability; CI, confidence intervals; CSVD, cerebral small vessel 
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Table S9. Table Showing Tests of Publication Bias for the Primary Outcomes 






 (15 studies) 
Diastolic BPV 
(14 studies) 
Begg-Mazumdar1 τ = 0.09, p = 0.67 τ = 0.53, p = 0.14 τ = -0.04, p = 0.84 τ = -0.24, p = 0.23 
Egger t(11) = 2.23, p = 0.047 t(4) = 4.06, p = 0.015 t(13) = 0.17, p = 0.87 t(12) = 0.77, p = 0.45 
Duval and Tweedie, estimate (95% CI) – n 
trimmed studies 
0.14 (0.11 to 0.17) 
 n = 2 
0.20 (0.06 to 0.35) 
 n = 2 
0.21 (0.13 to 0.28) 
n = 0 
0.13 (0.08 to 0.19) 
n = 0 
1. Kendall’s tau with continuity correction
BPV, blood pressure variability; CI, confidence interval; CSVD, cerebral small vessel disease; 
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Table S10. Assessment of Strength of Recommendations Using the GRADE Criteria 
 GRADE Item Odds for CSVD – systolic 
BPV 
Odds for CSVD diastolic 
BPV 
SMD in BPV 
systolic BPV 
SMD in BPV 
diastolic BPV 
Number of studies 13 6 15 14 
Effect size (95% CI) OR = 1.27 (1.14 to 1.42) OR = 1.30 (1.14 to 1.48) g = 0.21 (0.13 to 0.28) g = 0.13 (0.08 to 0.19) 
Risk of bias No No No No 
Inconsistency No No No No 
Indirectness No No No No 
Imprecision No No No No 
Publication bias Strongly suspected Strongly suspected Undetected Undetected 
Large effect No No No No 
Plausible confounding would 
change the effect  
No No No No 
Dose response gradient No No No No 
Quality of evidence Low Low Low Low 
GRADE assessment made using GRADE profiler 3.6.1 57 
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Table S11. Ancillary Analysis Results for Association Between BPV and WMH 
WMH outcome r or d 
family 
metric 




Total WMH r Systolic BPV 10 1, 3-5, 10, 14, 16, 19, 24, 26 r = 0.13 0.07 to 0.19 69 0.58 
r Systolic BP (mean) 8 1, 3, 5, 10, 14, 16, 19, 24 r = 0.11 0.04 to 0.18 63 
r Diastolic BPV 8 1, 5, 10, 14, 16, 19, 24, 26 r = 0.12 0.06 to 0.19 78 0.28 
r Diastolic BP (mean) 7 1, 5, 10, 14, 16, 19, 24  r = 0.18 0.11 to 0.24 67 
d Systolic BPV 8 9, 11, 14, 15, 17, 24, 26, 55 OR = 1.21 1.05 to 1.39 88 0.33 
d Systolic BP (mean) 6 9, 11, 14, 17, 24, 55 OR = 1.12 1.04 to 1.19 41 
d Diastolic BPV 3 14, 17, 24 OR = 1.18 1.09 to 1.28 0 0.47 
d Diastolic BP (mean) 3 14, 24, 51 OR = 1.15 1.10 to 1.19 0 
Deep WMH r Systolic BPV 3 10, 24, 26 r = 0.05 -0.06 to 0.16 58 0.86 
r Systolic BP (mean) 2 10, 24 r = 0.03 -0.10 to 0.17 0 
r Diastolic BPV 3 10, 24, 26 r = 0.03 -0.09 to 0.15 0 0.64 
r Diastolic BP (mean) 2 10, 24 r = 0.07 -0.07 to 0.22 80 
d Systolic BPV 3 15, 24, 51 OR = 1.12 0.99 to 1.27 0 0.29 
d Systolic BP (mean) 2 24, 51 OR = 1.31 1.00 to 1.71 0 
d Diastolic BPV 1 24 OR = 1.16 0.73 to 1.86 - - 
d Diastolic BP (mean) 124 OR = 2.11 1.31 to 3.38 - 
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WMH outcome r or d 
family 
metric 




r Systolic BP (mean) 2 10, 24 r = 0.09 0.04 to 0.14 0 
r Diastolic BPV 3 10, 24, 26 r = 0.10 0.03 to 0.16 11 0.89 
r Diastolic BP (mean) 2 10, 24 r = 0.10 0.03 to 0.18 24 
d Systolic BPV 3 15, 24, 26 OR = 1.27 1.09 to 1.47 0 - 
d Systolic BP (mean) 1 24 OR = 1.11 1.07 to 2.59 - 
d Diastolic BPV 1 24 OR = 1.61 1.01 to 2.58 - - 
d Diastolic BP (mean) 1 24 OR = 1.78 1.11 to 2.86 - 
Significant values in bold (when 2 or more studies) 
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Table S12. Ancillary Analysis Results for Odds of CSVD Stratified by Sub-type 
Ancillary analysis BP measure Studies n references OR 95% CI I2 p for 
heterogeneity 
between effects 
Incident CSVD Systolic BPV 3 14, 24, 27 0.95 0.76 to 1.19 0 0.18 
Systolic BP (per 10 mmHg increase) 2 14, 24 1.13 1.01 to 1.26 37 
Diastolic BPV 3 14, 24, 27 1.21 0.95 to 1.54 0 0.96 
Diastolic BP (per 5 mmHg increase) 2 14, 24 1.20 1.06 to 1.36 25 
CSVD progression Systolic BPV 3 14, 15, 27 1.39 1.00 to 1.95 89 - 
Systolic BP (per 10 mmHg increase) 1 14 1.06 1.00 to 1.12 - 
Diastolic BPV 2 14, 27 1.63 0.87 to 3.05 60 - 
Diastolic BP (per 5 mmHg increase) 1 14 1.15 1.09 to 1.21 - 
Lacune of presumed vascular 
origin  
Systolic BPV 4 6, 17, 24, 55 1.00 0.94 to 1.06 0 0.26 
Systolic BP (per 10 mmHg increase) 3 17, 24, 55 1.06 0.97 to 1.16 0 
Diastolic BPV 2 17, 24 1.06 0.87 to 1.29 0 0.67 
Diastolic BP (per 5 mmHg increase) 2 17, 24 1.18 0.75 to 1.85 59 
Cerebral microbleed Systolic BPV 1 17 1.30 0.77 to 2.19 - - 
Systolic BP (per 10 mmHg increase) 2 17, 26 1.19 1.00 to 1.42 0 
Diastolic BPV 1 17 1.77 1.06 to 2.96 - - 
Diastolic BP (per 5 mmHg increase) 1 17 0.88 0.49 to 1.58 - 




 http://ahajournals.org by on February 19, 2021
Ancillary analysis BP measure Studies n references OR 95% CI I2 p for 
heterogeneity 
between effects 
Systolic BP (per 10 mmHg increase) - - - - 
Diastolic BPV 1 28 1.81 1.25 to 2.62 - - 
Diastolic BP (per 5 mmHg increase) - - - - 
Significant values in bold (when 2 or more studies) 
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Figure S1. Flow chart of literature search and article selection process 
Figure describing the systematic search for articles, listing numbers excluded at each stage of 



























Records identified through database 
searching  
(n = 8,304) 
Additional records identified through other 
sources  
(n = 1) 
Records after duplicates removed 
(n = 8,175) 
Records screened 
(n = 8,175) 
Records excluded by 
title/abstract  
(n = 8,124) 
Case report/letter/review/editorial 
(868) 
Animal study (55) 
Language (215) 
In vivo (5) 
Child sample (74) 
Surgical intervention (130) 
Cancer sample (60) 
Genetic (161) 
Off-topic (6,556) 
Full-text articles assessed for 
eligibility  
(n = 51) 
Full-text articles excluded 
(n = 24)  
Acute stroke population (8) 
BPV data not available (5) 
Duplicate sample (5) 
CSVD not available (3) 
Degenerative neurology sample (2) 
No control group (1) 
Articles included in quantitative 
synthesis (meta-analysis) 
(n = 27) 
Additional studies included from 
full-text review  
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Figure S2. Funnel plot of odds for CSVD attributable to systolic BPV (trim and fill method) 
Non-shaded circles represent published effect sizes  
Shaded circles represent imputed effect sizes   
BPV, blood pressure variability; CSVD, cerebral small vessel disease;
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Figure S3. Funnel plot of odds for CSVD attributable to diastolic BPV (trim and fill method) 
Non-shaded circles represent published effect sizes  
Shaded circles represent imputed effect sizes 
BPV, blood pressure variability; CSVD, cerebral small vessel disease;
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Figure S4. Funnel plot of standardized mean differences in systolic BPV between persons with and without CSVD (trim and fill method) 
Non-shaded circles represent published effect sizes  
Shaded circles represent imputed effect sizes 
BPV, blood pressure variability; CSVD, cerebral small vessel disease;
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Figure S5. Funnel plot of standardized mean differences in diastolic BPV between persons with and without CSVD (trim and fill method) 
Non-shaded circles represent published effect sizes  
Shaded circles represent imputed effect sizes 
BPV, blood pressure variability; CSVD, cerebral small vessel diseases
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